CoChat

Bacteria and Host Interplay in Staphylococcus aureus Septic Arthritis and Sepsis

Jin, Tao, Mohammad, Majd, Pullerits, Rille, Ali, Abukar · 2021 · Pathogens
Cited by 76

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Staphylococcus aureus (S. aureus) infections are a major healthcare challenge and new treatment alternatives are needed. S. aureus septic arthritis, a debilitating joint disease, causes permanent joint dysfunction in almost 50% of the patients. S. aureus bacteremia is associated with higher mortalities than bacteremia caused by most other microbes and can develop to severe sepsis and death. The key to new therapies is understanding the interplay between bacterial virulence factors and host immune response, which decides the disease outcome. S. aureus produces numerous virulence factors that facilitate bacterial dissemination, invasion into joint cavity, and cause septic arthritis. Monocytes, activated by several components of S. aureus such as lipoproteins, are responsible for bone destructions. In S. aureus sepsis, cytokine storm induced by S. aureus components leads to the hyperinflammatory status, DIC, multiple organ failure, and later death. The immune suppressive therapies at the very early time point might be protective. However, the timing of treatment is crucial, as late treatment may aggravate the immune paralysis and lead to uncontrolled infection and death.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pathogens10020158

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 166

  1. Bien, 2011, Characterization of Virulence Factors of Staphylococcus aureus: Novel Function of Known Virulence Factors That Are Implicated in Activation of Airway Epithelial Proinflammatory Response, J. Pathog., 2011, 601905
  2. Ali, A. (2016). Biologics in Staphylococcus Aureus Arthritis. [Ph.D. Thesis, University of Gothenburg].
  3. Nanra, 2013, Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus, Hum. Vaccin. Immunother., 9, 480, 10.4161/hv.23223 · DOI
  4. Nilsson, 1997, The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis, Infect. Immun., 65, 4216, 10.1128/iai.65.10.4216-4221.1997 · DOI · Paper page
  5. Watts, 2005, Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence, Infect. Immun., 73, 3502, 10.1128/IAI.73.6.3502-3511.2005 · doi:10.1128/iai.73.6.3502-3511.2005
  6. Sharif, 2009, Staphylococcus aureus peptidoglycan tertiary structure from carbon-13 spin diffusion, J. Am. Chem. Soc., 131, 7023, 10.1021/ja808971c · DOI
  7. Vollmer, 2008, Peptidoglycan structure and architecture, FEMS Microbiol. Rev., 32, 149, 10.1111/j.1574-6976.2007.00094.x · DOI · Paper page
  8. Willey, J.M., Sherwood, L., and Woolverton, C.J. (2014). Prescott’s Microbiology, McGraw-Hill. [9th ed.].
  9. Grundling, 2006, Cross-linked peptidoglycan mediates lysostaphin binding to the cell wall envelope of Staphylococcus aureus, J. Bacteriol., 188, 2463, 10.1128/JB.188.7.2463-2472.2006 · DOI · Paper page
  10. Kashyap, 2011, Peptidoglycan recognition proteins kill bacteria by activating protein-sensing two-component systems, Nat. Med., 17, 676, 10.1038/nm.2357 · DOI · Paper page
  11. Liu, 2001, Staphylococcal peptidoglycans induce arthritis, Arthritis Res. Ther., 3, 375, 10.1186/ar330 · DOI · Paper page
  12. Dusad, 2013, Organic dust, lipopolysaccharide, and peptidoglycan inhalant exposures result in bone loss/disease, Am. J. Respir. Cell Mol. Biol., 49, 829, 10.1165/rcmb.2013-0178OC · DOI
  13. Mohammad, M., Nguyen, M.T., Engdahl, C., Na, M., Jarneborn, A., Hu, Z., Karlsson, A., Pullerits, R., Ali, A., and Gotz, F. (2019). The YIN and YANG of lipoproteins in developing and preventing infectious arthritis by Staphylococcus aureus. PLoS Pathog., 15. · DOI
  14. Bera, 2005, Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus, Mol. Microbiol., 55, 778, 10.1111/j.1365-2958.2004.04446.x · DOI · Paper page
  15. Sychantha, D., Jones, C.S., Little, D.J., Moynihan, P.J., Robinson, H., Galley, N.F., Roper, D.I., Dowson, C.G., Howell, P.L., and Clarke, A.J. (2017). In vitro characterization of the antivirulence target of Gram-positive pathogens, peptidoglycan O-acetyltransferase A (OatA). PLoS Pathog., 13. · DOI
  16. Baranwal, 2017, Impact of cell wall peptidoglycan O-acetylation on the pathogenesis of Staphylococcus aureus in septic arthritis, Int. J. Med. Microbiol., 307, 388, 10.1016/j.ijmm.2017.08.002 · DOI
  17. Reichmann, 2011, Location, synthesis and function of glycolipids and polyglycerolphosphate lipoteichoic acid in Gram-positive bacteria of the phylum Firmicutes, FEMS Microbiol. Lett., 319, 97, 10.1111/j.1574-6968.2011.02260.x · DOI · Paper page
  18. Morath, 2001, Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus, J. Exp. Med., 193, 393, 10.1084/jem.193.3.393 · DOI · Paper page
  19. Morath, 2002, Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release, J. Exp. Med., 195, 1635, 10.1084/jem.20020322 · DOI · Paper page
  20. Nguyen, 2016, Lipoproteins of Gram-Positive Bacteria: Key Players in the Immune Response and Virulence, Microbiol. Mol. Biol. Rev., 80, 891, 10.1128/MMBR.00028-16 · DOI · Paper page
  21. Sheldon, 2012, The iron-regulated staphylococcal lipoproteins, Front. Cell. Infect. Microbiol., 2, 41, 10.3389/fcimb.2012.00041 · DOI · Paper page
  22. Nguyen, 2017, Lipid moieties on lipoproteins of commensal and non-commensal staphylococci induce differential immune responses, Nat. Commun., 8, 2246, 10.1038/s41467-017-02234-4 · DOI
  23. Mohammad, 2020, The role of Staphylococcus aureus lipoproteins in hematogenous septic arthritis, Sci. Rep., 10, 7936, 10.1038/s41598-020-64879-4 · DOI
  24. Schmaler, 2009, Lipoproteins in Staphylococcus aureus mediate inflammation by TLR2 and iron-dependent growth in vivo, J. Immunol., 182, 7110, 10.4049/jimmunol.0804292 · DOI · Paper page
  25. Nguyen, M.T., Kraft, B., Yu, W., Demircioglu, D.D., Hertlein, T., Burian, M., Schmaler, M., Boller, K., Bekeredjian-Ding, I., and Ohlsen, K. (2015). The νSaα Specific Lipoprotein Like Cluster (lpl) of S. aureus USA300 Contributes to Immune Stimulation and Invasion in Human Cells. PLoS Pathog., 11. · doi:10.1371/journal.ppat.1005189
  26. Foster, 2014, Adhesion, invasion and evasion: The many functions of the surface proteins of Staphylococcus aureus, Nat. Rev. Microbiol., 12, 49, 10.1038/nrmicro3161 · DOI · Paper page
  27. Hair, 2010, Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis, Infect. Immun., 78, 1717, 10.1128/IAI.01065-09 · DOI · Paper page
  28. Josefsson, 2001, Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant, J. Infect. Dis., 184, 1572, 10.1086/324430 · DOI · Paper page
  29. Kobayashi, 2013, Staphylococcus aureus protein A promotes immune suppression, MBio, 4, e00764-13, 10.1128/mBio.00764-13 · DOI · Paper page
  30. Palmqvist, 2002, Protein A is a virulence factor in Staphylococcus aureus arthritis and septic death, Microb. Pathog., 33, 239, 10.1006/mpat.2002.0533 · DOI · Paper page
  31. Palmqvist, 2005, Fibronectin-binding proteins and fibrinogen-binding clumping factors play distinct roles in staphylococcal arthritis and systemic inflammation, J. Infect. Dis., 191, 791, 10.1086/427663 · doi:10.1086/427663
  32. Switalski, 1993, A collagen receptor on Staphylococcus aureus strains isolated from patients with septic arthritis mediates adhesion to cartilage, Mol. Microbiol., 7, 99, 10.1111/j.1365-2958.1993.tb01101.x · DOI · Paper page
  33. Patti, 1994, The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis, Infect. Immun., 62, 152, 10.1128/iai.62.1.152-161.1994 · DOI · Paper page
  34. Vanassche, 2011, Inhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus virulence, J. Thromb. Haemost., 9, 2436, 10.1111/j.1538-7836.2011.04529.x · DOI
  35. Na, M., Hu, Z., Mohammad, M., Stroparo, M.D.N., Ali, A., Fei, Y., Jarneborn, A., Verhamme, P., Schneewind, O., and Missiakas, D. (2020). The Expression of von Willebrand Factor-Binding Protein Determines Joint-Invading Capacity of Staphylococcus aureus, a Core Mechanism of Septic Arthritis. mBio, 11. · doi:10.1128/mbio.02472-20
  36. Hammel, 2007, The Staphylococcus aureus extracellular adherence protein (Eap) adopts an elongated but structured conformation in solution, Protein Sci., 16, 2605, 10.1110/ps.073170807 · DOI
  37. Zecconi, 2013, Staphylococcus aureus virulence factors in evasion from innate immune defenses in human and animal diseases, Immunol. Lett., 150, 12, 10.1016/j.imlet.2013.01.004 · DOI · Paper page
  38. Kwiecinski, 2013, Staphylokinase Promotes the Establishment of Staphylococcus aureus Skin Infections While Decreasing Disease Severity, J. Infect. Dis., 208, 990, 10.1093/infdis/jit288 · DOI
  39. Xu, 2012, Staphylococcal superantigens in colonization and disease, Front. Cell. Infect. Microbiol., 2, 52, 10.3389/fcimb.2012.00052 · DOI · Paper page
  40. McCormick, 2003, Functional analysis of the TCR binding domain of toxic shock syndrome toxin-1 predicts further diversity in MHC class II/superantigen/TCR ternary complexes, J. Immunol., 171, 1385, 10.4049/jimmunol.171.3.1385 · doi:10.4049/jimmunol.171.3.1385
  41. Abdelnour, 1994, Clonal expansion of T lymphocytes causes arthritis and mortality in mice infected with toxic shock syndrome toxin-1-producing staphylococci, Eur. J. Immunol., 24, 1161, 10.1002/eji.1830240523 · DOI · Paper page
  42. Dinges, 2000, Exotoxins of Staphylococcus aureus, Clin. Microbiol. Rev., 13, 16, 10.1128/CMR.13.1.16 · DOI · Paper page
  43. Omoe, 2013, Emetic potentials of newly identified staphylococcal enterotoxin-like toxins, Infect. Immun., 81, 3627, 10.1128/IAI.00550-13 · doi:10.1128/iai.00550-13
  44. Nilsson, 1999, Alpha-toxin and gamma-toxin jointly promote Staphylococcus aureus virulence in murine septic arthritis, Infect. Immun., 67, 1045, 10.1128/IAI.67.3.1045-1049.1999 · DOI · Paper page
  45. Cheung, 2014, Phenol-soluble modulins--critical determinants of staphylococcal virulence, FEMS Microbiol. Rev., 38, 698, 10.1111/1574-6976.12057 · DOI · Paper page
  46. Periasamy, 2012, How Staphylococcus aureus biofilms develop their characteristic structure, Proc. Natl. Acad. Sci. USA, 109, 1281, 10.1073/pnas.1115006109 · DOI · Paper page
  47. Peschel, 2013, Phenol-soluble modulins and staphylococcal infection, Nat. Rev. Microbiol., 11, 667, 10.1038/nrmicro3110 · DOI · Paper page
  48. Rasigade, J.P., Trouillet-Assant, S., Ferry, T., Diep, B.A., Sapin, A., Lhoste, Y., Ranfaing, J., Badiou, C., Benito, Y., and Bes, M. (2013). PSMs of hypervirulent Staphylococcus aureus act as intracellular toxins that kill infected osteoblasts. PLoS ONE, 8. · DOI
  49. Fournier, 2005, Recognition of Staphylococcus aureus by the innate immune system, Clin. Microbiol. Rev., 18, 521, 10.1128/CMR.18.3.521-540.2005 · DOI · Paper page
  50. Deng, 1999, Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis, Nat. Med., 5, 702, 10.1038/9554 · DOI · Paper page
  51. Sparwasser, 1997, Bacterial DNA causes septic shock, Nature, 386, 336, 10.1038/386336a0 · DOI · Paper page
  52. Joh, 1999, Role of fibronectin-binding MSCRAMMs in bacterial adherence and entry into mammalian cells, Matrix Biol., 18, 211, 10.1016/S0945-053X(99)00025-6 · DOI · Paper page
  53. An, Y.H., and Friedman, R.J. (2000). Handbook of Bacterial Adhesion Principles, Methods, and Applications, Humana Press.
  54. Chavakis, 2005, Staphylococcus aureus interactions with the endothelium: The role of bacterial “secretable expanded repertoire adhesive molecules” (SERAM) in disturbing host defense systems, Thromb. Haemost., 94, 278, 10.1160/TH05-05-0306 · DOI · Paper page
  55. Claes, 2014, Adhesion of Staphylococcus aureus to the vessel wall under flow is mediated by von Willebrand factor-binding protein, Blood, 124, 1669, 10.1182/blood-2014-02-558890 · doi:10.1182/blood-2014-02-558890
  56. Claes, 2017, Clumping factor A, von Willebrand factor-binding protein and von Willebrand factor anchor Staphylococcus aureus to the vessel wall, J. Thromb. Haemost., 15, 1009, 10.1111/jth.13653 · DOI · Paper page
  57. Bardoel, 2012, Evasion of Toll-like receptor 2 activation by staphylococcal superantigen-like protein 3, J. Mol. Med. (Berl.), 90, 1109, 10.1007/s00109-012-0926-8 · DOI
  58. Ibberson, 2014, Staphylococcus aureus hyaluronidase is a CodY-regulated virulence factor, Infect. Immun., 82, 4253, 10.1128/IAI.01710-14 · DOI · Paper page
  59. Kwiecinski, 2016, Staphylokinase Control of Staphylococcus aureus Biofilm Formation and Detachment Through Host Plasminogen Activation, J. Infect. Dis., 213, 139, 10.1093/infdis/jiv360 · DOI
  60. Fraser, J.D. (2011). Clarifying the mechanism of superantigen toxicity. PLoS Biol., 9. · DOI
  61. McCormick, 2001, Toxic shock syndrome and bacterial superantigens: An update, Annu. Rev. Microbiol., 55, 77, 10.1146/annurev.micro.55.1.77 · DOI · Paper page
  62. Marrack, 1990, The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells, J. Exp. Med., 171, 455, 10.1084/jem.171.2.455 · DOI · Paper page
  63. Kaempfer, 2013, CD28: Direct and critical receptor for superantigen toxins, Toxins (Basel), 5, 1531, 10.3390/toxins5091531 · DOI
  64. Gouaux, 1998, alpha-Hemolysin from Staphylococcus aureus: An archetype of beta-barrel, channel-forming toxins, J. Struct. Biol., 121, 110, 10.1006/jsbi.1998.3959 · DOI · Paper page
  65. Deng, 2001, Intracisternally localized bacterial DNA containing CpG motifs induces meningitis, J. Immunol., 167, 4616, 10.4049/jimmunol.167.8.4616 · DOI · Paper page
  66. Ali, 2015, Antibiotic-killed Staphylococcus aureus induces destructive arthritis in mice, Arthritis Rheumatol., 67, 107, 10.1002/art.38902 · DOI
  67. Verdrengh, 1997, Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus, Infect. Immun., 65, 2517, 10.1128/iai.65.7.2517-2521.1997 · DOI · Paper page
  68. Verdrengh, 2000, Role of macrophages in Staphylococcus aureus-induced arthritis and sepsis, Arthritis Rheum., 43, 2276, 10.1002/1529-0131(200010)43:10<2276::AID-ANR15>3.0.CO;2-C · doi:10.1002/1529-0131(200010)43:10<2276::aid-anr15>3.0.co;2-c
  69. Nilsson, 1999, Protective role of NK1.1+ cells in experimental Staphylococcus aureus arthritis, Clin. Exp. Immunol., 117, 63, 10.1046/j.1365-2249.1999.00922.x · DOI · Paper page
  70. Krishack, P.A., Louviere, T.J., Decker, T.S., Kuzel, T.G., Greenberg, J.A., Camacho, D.F., Hrusch, C.L., Sperling, A.I., and Verhoef, P.A. (2019). Protection against Staphylococcus aureus bacteremia-induced mortality depends on ILC2s and eosinophils. JCI Insight, 4. · DOI
  71. Abdelnour, 1994, Role of T lymphocytes in experimental Staphylococcus aureus arthritis, Scand. J. Immunol., 39, 403, 10.1111/j.1365-3083.1994.tb03392.x · DOI
  72. Bergmann, B., Fei, Y., Jirholt, P., Hu, Z., Bergquist, M., Ali, A., Lindholm, C., Ekwall, O., Churlaud, G., and Klatzmann, D. (2020). Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in mice. BMC Infect. Dis., 20. · DOI
  73. Gjertsson, 2000, Are B lymphocytes of importance in severe Staphylococcus aureus infections?, Infect. Immun., 68, 2431, 10.1128/IAI.68.5.2431-2434.2000 · DOI
  74. Wuescher, 2015, A novel conditional platelet depletion mouse model reveals the importance of platelets in protection against Staphylococcus aureus bacteremia, J. Thromb. Haemost., 13, 303, 10.1111/jth.12795 · DOI
  75. Piliponsky, 2019, Basophil-derived tumor necrosis factor can enhance survival in a sepsis model in mice, Nat. Immunol., 20, 129, 10.1038/s41590-018-0288-7 · DOI · Paper page
  76. Akira, 2006, Pathogen recognition and innate immunity, Cell, 124, 783, 10.1016/j.cell.2006.02.015 · DOI · Paper page
  77. Abbas, A.K., and Lichtman, A.H. (2009). Basic Immunology: Functions and Disorders of the Immune System, Saunders/Elsevier. [3rd ed.].
  78. Molne, 2000, Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus, Infect. Immun., 68, 6162, 10.1128/IAI.68.11.6162-6167.2000 · DOI · Paper page
  79. Mills, 2015, Anatomy of a discovery: m1 and m2 macrophages, Front. Immunol., 6, 212, 10.3389/fimmu.2015.00212 · DOI · Paper page
  80. Rath, 2014, Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages, Front. Immunol., 5, 532, 10.3389/fimmu.2014.00532 · DOI · Paper page
  81. Mosser, 2008, Exploring the full spectrum of macrophage activation, Nat. Rev. Immunol., 8, 958, 10.1038/nri2448 · DOI · Paper page
  82. Makita, 2015, IL-10 enhances the phenotype of M2 macrophages induced by IL-4 and confers the ability to increase eosinophil migration, Int. Immunol., 27, 131, 10.1093/intimm/dxu090 · DOI · Paper page
  83. Tanaka, 2005, Osteoblasts and osteoclasts in bone remodeling and inflammation, Curr. Drug Targets Inflamm. Allergy, 4, 325, 10.2174/1568010054022015 · DOI · Paper page
  84. Ogata, 1999, A novel role of IL-15 in the development of osteoclasts: Inability to replace its activity with IL-2, J. Immunol., 162, 2754, 10.4049/jimmunol.162.5.2754 · DOI · Paper page
  85. Djaafar, 2010, Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice, Arthritis Rheum., 62, 3300, 10.1002/art.27645 · DOI · Paper page
  86. Henningsson, 2012, Interleukin 15 mediates joint destruction in Staphylococcus aureus arthritis, J. Infect. Dis., 206, 687, 10.1093/infdis/jis295 · DOI
  87. Verdrengh, 2010, RANKL-targeted therapy inhibits bone resorption in experimental Staphylococcus aureus-induced arthritis, Bone, 46, 752, 10.1016/j.bone.2009.10.028 · DOI
  88. Deng, 2000, The major role of macrophages and their product tumor necrosis factor alpha in the induction of arthritis triggered by bacterial DNA containing CpG motifs, Arthritis Rheum., 43, 2283, 10.1002/1529-0131(200010)43:10<2283::AID-ANR16>3.0.CO;2-9 · doi:10.1002/1529-0131(200010)43:10<2283::aid-anr16>3.0.co;2-9
  89. Small, 2008, NK cells play a critical protective role in host defense against acute extracellular Staphylococcus aureus bacterial infection in the lung, J. Immunol., 180, 5558, 10.4049/jimmunol.180.8.5558 · DOI · Paper page
  90. Laarman, 2011, Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion, J. Immunol., 186, 6445, 10.4049/jimmunol.1002948 · DOI · Paper page
  91. Laarman, 2010, Complement inhibition by gram-positive pathogens: Molecular mechanisms and therapeutic implications, J. Mol. Med. (Berl.), 88, 115, 10.1007/s00109-009-0572-y · DOI · Paper page
  92. Sakiniene, 1999, Complement depletion aggravates Staphylococcus aureus septicaemia and septic arthritis, Clin. Exp. Immunol., 115, 95, 10.1046/j.1365-2249.1999.00771.x · DOI
  93. Na, M., Jarneborn, A., Ali, A., Welin, A., Magnusson, M., Stokowska, A., Pekna, M., and Jin, T. (2016). Deficiency of the complement component 3 but not factor B aggravates Staphylococcus aureus septic arthritis in mice. Infect. Immun. · DOI
  94. Andersen, 2006, Cytotoxic T cells, J. Investig. Dermatol., 126, 32, 10.1038/sj.jid.5700001 · DOI · Paper page
  95. Sakaguchi, 2008, Regulatory T cells and immune tolerance, Cell, 133, 775, 10.1016/j.cell.2008.05.009 · DOI · Paper page
  96. Tesmer, 2008, Th17 cells in human disease, Immunol. Rev., 223, 87, 10.1111/j.1600-065X.2008.00628.x · DOI · Paper page
  97. Kidd, 2003, Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease, Altern. Med. Rev., 8, 223
  98. Romagnani, 1999, Th1/Th2 cells, Inflamm. Bowel Dis., 5, 285, 10.1097/00054725-199911000-00009 · DOI · Paper page
  99. Oosterwegel, 1999, The role of CTLA-4 in regulating Th2 differentiation, J. Immunol., 163, 2634, 10.4049/jimmunol.163.5.2634 · DOI · Paper page
  100. Ali, 2015, CTLA4 Immunoglobulin but Not Anti-Tumor Necrosis Factor Therapy Promotes Staphylococcal Septic Arthritis in Mice, J. Infect. Dis., 212, 1308, 10.1093/infdis/jiv212 · DOI
  101. Parker, 2015, CD4+ T cells promote the pathogenesis of Staphylococcus aureus pneumonia, J. Infect. Dis., 211, 835, 10.1093/infdis/jiu525 · DOI
  102. Jin, 2019, A novel mouse model for septic arthritis induced by Pseudomonas aeruginosa, Sci. Rep., 9, 16868, 10.1038/s41598-019-53434-5 · DOI
  103. Henningsson, 2010, Interleukin-17A during local and systemic Staphylococcus aureus-induced arthritis in mice, Infect. Immun., 78, 3783, 10.1128/IAI.00385-10 · DOI
  104. Kwiecinski, 2013, Sulfatide attenuates experimental Staphylococcus aureus sepsis through a CD1d-dependent pathway, Infect. Immun., 81, 1114, 10.1128/IAI.01334-12 · DOI
  105. Sonnenberg, 2019, Functional interactions between innate lymphoid cells and adaptive immunity, Nat. Rev. Immunol., 19, 599, 10.1038/s41577-019-0194-8 · DOI · Paper page
  106. Ali, 2017, Platelets Mediate Host Defense against Staphylococcus aureus through Direct Bactericidal Activity and by Enhancing Macrophage Activities, J. Immunol., 198, 344, 10.4049/jimmunol.1601178 · DOI · Paper page
  107. Hultgren, 1998, TNF/lymphotoxin-alpha double-mutant mice resist septic arthritis but display increased mortality in response to Staphylococcus aureus, J. Immunol., 161, 5937, 10.4049/jimmunol.161.11.5937 · DOI · Paper page
  108. Hultgren, 2002, Critical role of signaling through IL-1 receptor for development of arthritis and sepsis during Staphylococcus aureus infection, J. Immunol., 168, 5207, 10.4049/jimmunol.168.10.5207 · DOI · Paper page
  109. Lenski, 2014, The significance of interleukin-6 and lactate in the synovial fluid for diagnosing native septic arthritis, Acta Orthop. Belg., 80, 18
  110. Hultgren, 2001, Role of IL-12 in Staphylococcus aureus-triggered arthritis and sepsis, Arthritis Res., 3, 41, 10.1186/ar138 · DOI · Paper page
  111. Hultgren, 1998, Staphylococcus aureus-induced septic arthritis and septic death is decreased in IL-4-deficient mice: Role of IL-4 as promoter for bacterial growth, J. Immunol., 160, 5082, 10.4049/jimmunol.160.10.5082 · DOI · Paper page
  112. Hultgren, 1999, Outcome of Staphylococcus aureus-triggered sepsis and arthritis in IL-4-deficient mice depends on the genetic background of the host, Eur. J. Immunol., 29, 2400, 10.1002/(SICI)1521-4141(199908)29:08<2400::AID-IMMU2400>3.0.CO;2-E · doi:10.1002/(sici)1521-4141(199908)29:08<2400::aid-immu2400>3.0.co;2-e
  113. Gjertsson, 2002, Interleukin-10 ameliorates the outcome of Staphylococcus aureus arthritis by promoting bacterial clearance, Clin. Exp. Immunol., 130, 409, 10.1046/j.1365-2249.2002.01999.x · doi:10.1046/j.1365-2249.2002.01999.x
  114. Zhao, 1998, The dual role of interferon-gamma in experimental Staphylococcus aureus septicaemia versus arthritis, Immunology, 93, 80, 10.1046/j.1365-2567.1998.00407.x · DOI · Paper page
  115. Jarneborn, 2020, Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice, Sci. Rep., 10, 10891, 10.1038/s41598-020-67928-0 · DOI
  116. Davis, 2011, The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus, J. Interferon Cytokine Res., 31, 781, 10.1089/jir.2011.0047 · DOI
  117. Osiri, 1998, IL-1beta, IL-6 and TNF-alpha in synovial fluid of patients with non-gonococcal septic arthritis, Asian Pac. J. Allergy Immunol., 16, 155
  118. Na, M., Wang, W., Fei, Y., Josefsson, E., Ali, A., and Jin, T. (2017). Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice. PLoS ONE, 12. · DOI
  119. Jacques, 2006, The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation, Vitam. Horm., 74, 371, 10.1016/S0083-6729(06)74016-X · DOI · Paper page
  120. Zhao, 1995, Impact of interferon-gamma receptor deficiency on experimental Staphylococcus aureus septicemia and arthritis, J. Immunol., 155, 5736, 10.4049/jimmunol.155.12.5736 · DOI · Paper page
  121. 1998, Cytokines induce the development of functionally heterogeneous T helper cell subsets, Immunity, 8, 275, 10.1016/S1074-7613(00)80533-6 · DOI · Paper page
  122. Ivanov, 2009, Interleukin-17 as a drug target in human disease, Trends Pharmacol. Sci., 30, 95, 10.1016/j.tips.2008.11.004 · DOI
  123. Sharff, 2013, Clinical management of septic arthritis, Curr. Rheumatol. Rep., 15, 332, 10.1007/s11926-013-0332-4 · DOI
  124. Tarkowski, 2006, Infection and musculoskeletal conditions: Infectious arthritis, Best Pract. Res. Clin. Rheumatol., 20, 1029, 10.1016/j.berh.2006.08.001 · DOI
  125. Goldenberg, 1998, Septic arthritis, Lancet, 351, 197, 10.1016/S0140-6736(97)09522-6 · DOI · Paper page
  126. Balsa, 2011, Septic arthritis, Best Pract. Res. Clin. Rheumatol., 25, 407, 10.1016/j.berh.2011.02.001 · DOI · Paper page
  127. Mathews, 2010, Bacterial septic arthritis in adults, Lancet, 375, 846, 10.1016/S0140-6736(09)61595-6 · DOI · Paper page
  128. Morgan, 1996, An 18 year clinical review of septic arthritis from tropical Australia, Epidemiol. Infect., 117, 423, 10.1017/S0950268800059070 · DOI · Paper page
  129. Fowler, 1998, Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: Experience with 244 patients, Clin. Infect. Dis., 27, 478, 10.1086/514686 · DOI · Paper page
  130. Marr, 1998, Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients, Kidney Int., 54, 1684, 10.1046/j.1523-1755.1998.00134.x · DOI · Paper page
  131. Naber, 2009, Staphylococcus aureus bacteremia: Epidemiology, pathophysiology, and management strategies, Clin. Infect. Dis., 48, S231, 10.1086/598189 · DOI · Paper page
  132. Holland, 2014, Clinical management of Staphylococcus aureus bacteremia: A review, JAMA, 312, 1330, 10.1001/jama.2014.9743 · DOI · Paper page
  133. Martin, 2012, Sepsis, severe sepsis and septic shock: Changes in incidence, pathogens and outcomes, Expert. Rev. Anti Infect. Ther., 10, 701, 10.1586/eri.12.50 · DOI · Paper page
  134. Kuiper, 2003, Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock, Clin. Microbiol. Rev., 16, 379, 10.1128/CMR.16.3.379-414.2003 · DOI · Paper page
  135. Huttunen, 2011, New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis, J. Infect., 63, 407, 10.1016/j.jinf.2011.08.004 · DOI
  136. Semeraro, 2010, Sepsis-associated disseminated intravascular coagulation and thromboembolic disease, Mediterr. J. Hematol. Infect. Dis., 2, e2010024, 10.4084/mjhid.2010.024 · DOI · Paper page
  137. Romling, 2012, Biofilm infections, their resilience to therapy and innovative treatment strategies, J. Intern. Med., 272, 541, 10.1111/joim.12004 · DOI · Paper page
  138. Stoodley, 2008, Direct demonstration of viable Staphylococcus aureus biofilms in an infected total joInt. arthroplasty. A case report, J. Bone Joint Surg. Am., 90, 1751, 10.2106/JBJS.G.00838 · DOI · Paper page
  139. Dastgheyb, 2015, Effect of biofilms on recalcitrance of staphylococcal joInt. infection to antibiotic treatment, J. Infect. Dis., 211, 641, 10.1093/infdis/jiu514 · DOI · Paper page
  140. Davies, 2003, Understanding biofilm resistance to antibacterial agents, Nat. Rev. Drug Discov., 2, 114, 10.1038/nrd1008 · DOI · Paper page
  141. Kwiecinski, 2015, Biofilm formation by Staphylococcus aureus isolates from skin and soft tissue infections, Curr. Microbiol., 70, 698, 10.1007/s00284-014-0770-x · DOI
  142. Otto, 2013, Staphylococcal infections: Mechanisms of biofilm maturation and detachment as critical determinants of pathogenicity, Annu. Rev. Med., 64, 175, 10.1146/annurev-med-042711-140023 · DOI · Paper page
  143. Kwiecinski, 2015, Tissue Plasminogen Activator Coating on Implant Surfaces Reduces Staphylococcus aureus Biofilm Formation, Appl. Environ. Microbiol., 82, 394, 10.1128/AEM.02803-15 · DOI
  144. Libertucci, 2019, The role of the microbiota in infectious diseases, Nat. Microbiol., 4, 35, 10.1038/s41564-018-0278-4 · DOI · Paper page
  145. Sewankambo, 1997, HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis, Lancet, 350, 546, 10.1016/S0140-6736(97)01063-5 · DOI · Paper page
  146. Hyoju, S.K., Zaborin, A., Keskey, R., Sharma, A., Arnold, W., van den Berg, F., Kim, S.M., Gottel, N., Bethel, C., and Charnot-Katsikas, A. (2019). Mice Fed an Obesogenic Western Diet, Administered Antibiotics, and Subjected to a Sterile Surgical Procedure Develop Lethal Septicemia with Multidrug-Resistant Pathobionts. mBio, 10. · DOI · Paper page
  147. Jubair, 2018, Modulation of Inflammatory Arthritis in Mice by Gut Microbiota Through Mucosal Inflammation and Autoantibody Generation, Arthritis Rheumatol., 70, 1220, 10.1002/art.40490 · DOI · Paper page
  148. Breban, 2017, Faecal microbiota study reveals specific dysbiosis in spondyloarthritis, Ann. Rheum. Dis., 76, 1614, 10.1136/annrheumdis-2016-211064 · DOI · Paper page
  149. Ulici, 2018, Osteoarthritis induced by destabilization of the medial meniscus is reduced in germ-free mice, Osteoarthr. Cartil., 26, 1098, 10.1016/j.joca.2018.05.016 · DOI
  150. Henrotin, Y., Patrier, S., Pralus, A., Roche, M., and Nivoliez, A. (2019). Protective Actions of Oral Administration of Bifidobacterium longum CBi0703 in Spontaneous Osteoarthritis in Dunkin Hartley Guinea Pig Model. Cartilage, 1947603519841674. · doi:10.1177/1947603519841674
  151. Rios, 2019, Protective effect of prebiotic and exercise intervention on knee health in a rat model of diet-induced obesity, Sci. Rep., 9, 3893, 10.1038/s41598-019-40601-x · DOI
  152. Kaandorp, 1995, Risk factors for septic arthritis in patients with joint disease. A prospective study, Arthritis Rheum., 38, 1819, 10.1002/art.1780381215 · DOI · Paper page
  153. Walsh, 2010, Bone remodeling in rheumatic disease: A question of balance, Immunol. Rev., 233, 301, 10.1111/j.0105-2896.2009.00857.x · DOI · Paper page
  154. Fei, 2011, The combination of a tumor necrosis factor inhibitor and antibiotic alleviates staphylococcal arthritis and sepsis in mice, J. Infect. Dis., 204, 348, 10.1093/infdis/jir266 · DOI
  155. Ali, A., Na, M., Svensson, M.N., Magnusson, M., Welin, A., Schwarze, J.C., Mohammad, M., Josefsson, E., Pullerits, R., and Jin, T. (2015). IL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice. PLoS ONE, 10. · DOI · Paper page
  156. Okusawa, 1988, Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition, J. Clin. Investig., 81, 1162, 10.1172/JCI113431 · DOI · Paper page
  157. Wang, 1999, HMG-1 as a late mediator of endotoxin lethality in mice, Science, 285, 248, 10.1126/science.285.5425.248 · DOI · Paper page
  158. Fisher, 1996, Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group, N. Engl. J. Med., 334, 1697, 10.1056/NEJM199606273342603 · DOI · Paper page
  159. Richter, 2016, Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis, Ann. Rheum. Dis., 75, 1667, 10.1136/annrheumdis-2015-207838 · DOI · Paper page
  160. Fattahi, 2017, Understanding Immunosuppression after Sepsis, Immunity, 47, 3, 10.1016/j.immuni.2017.07.007 · DOI
  161. Lowy, 1998, Staphylococcus aureus infections, N. Engl. J. Med., 339, 520, 10.1056/NEJM199808203390806 · DOI · Paper page
  162. Miller, 2020, Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms, FEMS Microbiol. Rev., 44, 123, 10.1093/femsre/fuz030 · DOI · Paper page
  163. Smith, 1997, Staphylococcal septic arthritis: Antibiotic and nonsteroidal anti-inflammatory drug treatment in a rabbit model, J. Orthop. Res., 15, 919, 10.1002/jor.1100150619 · doi:10.1002/jor.1100150619
  164. Ferreira, 2018, A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation, Am. J. Hum. Genet., 103, 553, 10.1016/j.ajhg.2018.09.003 · DOI
  165. Sakiniene, 1996, Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental Staphylococcus aureus arthritis, Arthritis Rheum., 39, 1596, 10.1002/art.1780390921 · DOI · Paper page
  166. Odio, 2003, Double blind, randomized, placebo-controlled study of dexamethasone therapy for hematogenous septic arthritis in children, Pediatr. Infect. Dis. J., 22, 883, 10.1097/01.inf.0000091293.32187.7b · DOI

Cited by

See all 76

Metadata

Authors
Jin, T., Mohammad, M., Pullerits, R., & Ali, A.
Venue
Pathogens
Publisher
MDPI AG
Published
2021-02-03
Volume
10
Issue
2
Pages
158
ISSN
2076-0817
Cited by
76
References
21
Language
en
Funders
Vetenskapsrådet (2019-01135)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.